8-K current report · filed Aug 17, 2026

Fulcrum Therapeutics, Inc. (FULC) 8-K Current Report: August 17, 2026

Item EX-99.1Item EX-99.2Item 5.01Item 5.02Item 7.01Item 1.01Item 3.02FULC overview

Short answer

Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on August 17, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). Merger transforms Fulcrum into Slate Medicines, with Slate holders owning 55.9% and existing Fulcrum holders only 5.0% fully diluted.

Fulcrum Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Merger transforms Fulcrum into Slate Medicines, with Slate holders owning 55.9% and existing Fulcrum holders only 5.0% fully diluted
  • $245.0M concurrent investment provides planned capitalization, with investors receiving 39.1% of the combined company
  • Fulcrum expects a $270M aggregate cash dividend before closing, subject to adjustment, materially reducing cash available to legacy shareholders
  • Slate will control the post-closing board, with all five directors designated by Slate
  • Closing depends on stockholder approvals, Nasdaq listing, registration effectiveness, reverse split, and minimum $0 Fulcrum net cash; termination fees up to $15M

Item 3.02 · Unregistered Sales of Equity Securities

  • Slate shares issued in Concurrent Investment through private placements, exempt from SEC registration under Section 4(a)(2) and/or Regulation D
  • Unregistered issuance limits immediate public offering requirements but may create future dilution for existing Fulcrum shareholders
  • Investment terms and share impact require review of the referenced Item 1.01 agreement

Item 5.01 · Changes in Control of Registrant

  • Item 5.01 cross-references Item 1.01 for any control-change information
  • Investor impact depends on the transaction details disclosed under Item 1.01

Item 5.02 · Departure/Election of Directors or Officers

  • Item 5.02 contains no standalone officer or director change details
  • Investor-relevant information is incorporated from Item 1.01, requiring review of the material agreement terms

Item 7.01 · Regulation FD Disclosure

  • Fulcrum and Slate announced execution of a merger agreement and purchase agreement on August 17, 2026
  • Transaction terms include exchange-ratio adjustments tied to Fulcrum’s closing net cash, affecting ownership and potential cash distributions
  • Concurrent Slate private placement financing remains a closing condition and is intended to support operations into 2029
  • Combined company plans Nasdaq listing, with SLTE-1009 development and regulatory milestones central to value creation
  • Investors should monitor Form S-4, stockholder approval, regulatory clearances, financing completion and final net-cash determination

Item EX-99.1 · Exhibit EX-99.1

  • All-stock merger shifts Fulcrum into Slate Medicines, focusing the public company on migraine therapeutics
  • Fulcrum holders expected to own 5.0%; Slate holders 95.0%, subject to adjustment based on Fulcrum net cash
  • Estimated $270.0 million cash dividend to pre-merger Fulcrum stockholders, with approximately $20.3 million contributed at closing
  • $245 million oversubscribed private placement expected to fund operations into 2029 and advance SLTE-1009 clinical studies
  • Fourth-quarter 2026 closing requires shareholder approvals, SEC registration effectiveness, and antitrust clearance

Item EX-99.2 · Exhibit EX-99.2

  • Proposed stock-for-stock merger creates Slate Medicines, with Fulcrum holders receiving an estimated 5.0% of the combined company
  • $245 million private placement led by Frazier Life Sciences, funding Slate’s migraine pipeline and materially reshaping Fulcrum’s capital structure
  • Pre-merger Fulcrum cash dividend tied to net cash above $20.3 million, potentially returning excess liquidity before closing
  • SLTE-1009 advancing toward Phase 1 in 2H26 and Phase 2 migraine studies, with potential monthly or quarterly subcutaneous dosing
  • Closing targeted for Q4 2026, subject to approvals and conditions, with Nasdaq listing and cash runway anticipated into 2029

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Fulcrum Therapeutics, Inc. 8-K filings

Get the next FULC 8-K as it lands

Follow FULC for push alerts, or ask the research agent what this filing means.